Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

(2010) V. Novotny-Diermayr et al.   MOLECULAR CANCER THERAPEUTICS

HDAC inhibitor-based therapies and haematological malignancy

(2009) L. Stimson et al.   ANNALS OF ONCOLOGY

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

Histone Deacetylase Inhibitors Reverse SS18-SSX-Mediated Polycomb Silencing of the Tumor Suppressor Early Growth Response 1 in Synovial Sarcoma

(2008) J. M. Lubieniecka et al.   CANCER RESEARCH

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH

413 POSTER A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies

(2008) W.P. Yong et al.   EJC SUPPLEMENTS

83 POSTER A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor

(2008) V. Novotny-Diermayr et al.   EJC SUPPLEMENTS

Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer

(2008) Mari Björkman et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

(2008) Lillian L. Siu et al.   JOURNAL OF CLINICAL ONCOLOGY